je.st
news
Tag: merck
Merck & Co sells consumer unit to Bayer for $14 billion
2014-05-06 13:34:46| Food - Topix.net
Merck & Co Inc has agreed to sell its consumer care business to Germany's Bayer AG for $14.2 billion, the companies said on Tuesday, adding to a string of major cross-border healthcare deals.
Tags: for
unit
consumer
billion
Bayer to pay $14.2bn for Merck unit
2014-05-06 12:59:04| BBC News | Business | UK Edition
Germany's Bayer agrees to pay $14.2bn (8.4bn) to buy US rival Merck's consumer care business, which owns the Coppertone and Dr Scholl's brands.
Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion
2014-05-06 12:00:00| Merck.com - Financial News
Dateline City: BOSTON Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Mercks existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Pam Eisele, 267-305-3558orInvestors:Joe Romanelli, 908-423-5185Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: business
care
sale
consumer
Bayer Said to Be in Exclusive Talks for Merck Consumer Unit
2014-05-02 14:09:30| Biotech - Topix.net
Bayer AG is in exclusive talks to acquire Merck & Co.' s consumer business and is prepared to pay about $14 billion for the division, people with knowledge of the matter said.
Tags: unit
consumer
exclusive
talks
Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis
2014-05-02 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of Progression-Free Survival (PFS) in patients with platinum-resistant ovarian cancer. Language: English Contact: MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more
Tags: following
analysis
independent
trial
Sites : [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] next »